Insider · CIK 0001790933
James Brian Windsor
Files at RNTX (Rein Therapeutics, Inc.). First filing Dec 9, 2024, latest May 13, 2026.
In brief
James Brian Windsor files SEC Form 4 as CEO, president and director at RNTX (Rein Therapeutics, Inc.). Since Dec 9, 2024, James Brian Windsor has reported 2 open-market buys worth $26k and 0 open-market sells worth $0, the latest filed on May 13, 2026.
A track record needs three past buys with six months of prices behind them; James Brian Windsor has 0, so none is measured yet.
The newest scored trade: bought $25k of RNTX on Apr 30, 2026, filed May 13, 2026, scored 38 (weak). In the last 12 months: 1 buy worth $25k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RNTX: Rein Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | RNTXbuy Rein Therapeutics, Inc. | $25k 25,000 shares | +1222% | +27% from low-43% from high | |
| 33Weak | RNTXbuy Rein Therapeutics, Inc. | $898 400 shares | - | - |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | RNTX Rein Therapeutics, Inc. | POpen-market purchase Common stock , $0.001 par value | +25,000 | $1.00 | $25k | 27,046 | May 13, 2026 |
| May 8, 2026 | RNTX Rein Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | -150,000 | $0.00 | $0 | 150,000 | May 13, 2026 |
| Dec 5, 2024 | RNTX Rein Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By son | +239 | $2.24 | $535 | 239 | Dec 9, 2024 |
| Dec 5, 2024 | RNTX Rein Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By son | +161 | $2.25 | $362 | 161 | Dec 9, 2024 |
| Dec 2, 2024 | RNTX Rein Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +517,500 | $0.00 | $0 | 517,500 | Dec 4, 2024 |
Questions about James Brian Windsor
Answered from the filings on this page, as of the latest one.
Is James Brian Windsor buying or selling?
In the last 12 months James Brian Windsor reported 1 open-market buy worth $25k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $25k of RNTX on Apr 30, 2026. Grants, option exercises and tax withholding are not counted.
How did James Brian Windsor's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Brian Windsor has 0.
Where does James Brian Windsor file Form 4?
James Brian Windsor has filed Form 4 at RNTX (Rein Therapeutics, Inc.) as See Remarks. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.